Top news from MedWatch this week

Miss anything?

Photo: MedWatch


Genmab CEO strives to maintain company culture as staff count grows to 1,500

Genmab CEO: ”We can do things in a smarter way than pharma companies”

Analyst: Genmab’s Darzalex income coming in faster than expected


Demant downgrades after revenue disappoints

Demant CEO highlights strong performance from Diagnostics, acknowledges Communications letdown

Demant rejects criticisms of lobbying efforts against OTC channel: ”That’s how America works”

GN Hearing launches new product platform

GN Hearing to utilize pandemic experiences in new product launch

Sonova downgrades, blames high costs and weak results from key markets


GN Hearing downgrades organic growth forecast

Vyepti study misfire makes for learning experience for Lundbeck

Key products generate strong Q2 result for Lundbeck

Turbulent markets won’t prevent Sonova’s grand platform launch

Coloplast presents strong Q3 figures

New GN product to solve challenges for hearing aid users, says CEO

Hearing aids to reach millions with FDA over-the-counter approval


Leo Pharma appoints new CFO

Novo Nordisk diabetes drug hit by supply issues

GN seeks OTC approval for flagship product

Demant plans to increase investments in China

GN Hearing wants to outperform restrained US market in H2

Lundbeck sued in the US – again


Lundbeck gears up as Alzheimer’s agitation approval looks attainable

GN Hearing predicts slow start for OTC market

Some hearing aid manufacturers raise prices

Manufacturers mull over OTC options as Best Buy announces new hearing aid line

Sonova acquires Chinese hearing clinics chain

Coloplast’s important growth market still curbed by the pandemic

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Latest news

See all jobs